ClinicalTrials.gg
CompletedNCT03301155Updated May 6, 2020Results posted

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

A Phase 4 interventional study of Anaferon for children and Placebo in Preventive Medicine, sponsored by Materia Medica Holding. Completed at 33 sites in 2 countries. Open to participants aged 1 Month to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-06.

Sponsored by Materia Medica Holding · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,036
Allocation
Randomized
Ages
1 Month to 6 Years
Sex
All
01

Study summary

The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.

Read the detailed description

Design: an international, multicenter, double-blind, placebo-controlled, randomized study in parallel groups.

The study will enroll children of either gender aged of 1 month to 6 years old. Children can participate in the study, regardless of the frequency of previous ARVI. A potential study participant should not be in the incubation (if known), prodromal, acute/subacute periods of any infectious disease (except for the recovery period). Schedule for enrollment of participants: during the period of a seasonal rise in influenza/ARVI incidence in the Russian Federation and the Republic of Uzbekistan. Screening and randomization of participants will be subject to availability of official information on the incidence of influenza/ARVI in the relevant study region.

The doctor makes the first visit to the participant in the medical center or at home. After the parent/adoptive parent signs the information sheet (informed consent form), the doctor evaluates the possibility of the participant being included in the trial. If the child meets all the inclusion criteria and does not have all non-inclusion criteria, then he/she is included in the study, the doctor fills in Clinical Research Form. At visit 1 (Day 1), the participant is randomized into one of two groups: the 1st group participants will take Anaferon for children according to the preventive regimen for 12 weeks; the 2nd group participants will take Placebo according to the regimen of Anaferon for 12 weeks.

In total, the study participant will be observed for 12 weeks (screening and randomization up to 1 day, preventive treatment for 12 weeks).

During the observation period at 4 (Visit 2), 8 (Visit 3) and 12 (Visit 4) weeks, three visits are planned.

Visits 2 (Week 4 ± 3 days) and 3 (Week 8 ± 3 days) are conducted in the form of a telephone survey of parents/adoptive parents about the participant's health status, presence/absence of symptoms of influenza/ARVI, possible use of antibacterial drugs and/or hospitalization during the course preventive therapy.

Visit 4 (Week 12 ± 3 days) is carried out at home or in a medical center; the doctor collects complaints, examines the participant, registers concomitant therapy, assesses the compliance of the therapy.

If in the period from 2 to 12 weeks a participant falls ill with influenza/ARVI, then he/she prematurely completes participation in the study (as having reached the primary endpoint). A participant is considered fallen ill with influenza/ARVI if the doctor identifies the following symptoms: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/impaired behavior/weakness; headache; chills) and at least one respiratory symptom (runny nose; nasal stuffiness; hoarseness/husky voice; sore throat; cough). In this case, the doctor makes an unscheduled visit (at home or in a medical center), which is final. During the visit, the doctor carries out the procedures of Visit 4. A nasopharyngeal swab is taken to identify the most common pathogens of influenza/ARVI.

If ARVI/influenza occurs within the first seven days from the onset of preventive therapy, the disease will not be recorded as an adverse event and will not be taken into account to evaluate the efficacy of the study drug, since an early manifestation of influenza/ARVI may indicate that the participant was included in the study when he/she was in the incubation period of an infectious disease.

During the study, concomitant therapy for underlying chronic conditions, as well as routine vaccination of the participant, are allowed, with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".

02

Conditions studied

  • Preventive Medicine
03

In context

Lead sponsor

Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children of either gender aged from 1 month to 6 years old.
  2. The absence of clinical symptoms of any infectious disease, but not earlier than 14 days from its onset.
  3. Seasonal rise in ARVI incidence, confirmed by official information.
  4. An information sheet ( form) for the subject participation in the clinical trial signed by one parent/adopter of the patient.

Exclusion criteria

Exclusion Criteria:

  1. Acute or subacute period of infectious disease of any etiology (viral, bacterial, fungal, etc.) and localization (including upper and lower respiratory tract infection, meningitis, sepsis, otitis media, urinary tract infection, intestinal infection, etc.).
  2. History of (verified previously) or current suspected conditions such as:

    • primary or secondary immunodeficiency;
    • bronchopulmonary dysplasia, primary ciliary dyskinesia, cystic fibrosis, other chronic pulmonary diseases;
    • malformations of the respiratory and ENT organs (ear, throat, mouth, tongue, larynx, trachea, neck and salivary and thyroid glands, etc.);
    • immunopathological diseases (including Marshall syndrome, Behсet's syndrome, Kawasaki disease, etc.);
    • hematological diseases (including agranulocytosis, leukemia);
    • oncologic conditions.
  3. Exacerbated or decompensated of chronic diseases affecting the patienrt's ability to participate in the clinical trial.
  4. Malabsorption syndrome, including congenital or acquired lactase or another disaccharide deficiency, galactosemia.
  5. Allergy/intolerance to any component of the study drug.
  6. Course administration of the drug products specified in the section 'Prohibited concomitant medications' within 2 weeks prior to enrollment.
  7. Children whose parents/adopter parents will fail to comply with the observation requirements of the trial or with the intake regimen of the study drug, from the investigator's point of view.
  8. Participation in other clinical trials within 3 month prior to enrollment in the study.
  9. The patient's parent/adopter parent is a member of the research team of the site directly involved in the study or a close relative of an investigator. Close relatives are defined as husband/wife, parents, children, brothers (sisters) regardless of whether they are biological or adopted.
  10. The patient's parent/adopter parent works for OOO "NPF "MATERIA MEDICA HOLDING" (i.e., the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,036 participants (actual)

Study arms

  • Experimental
    Anaferon for children

    Tablet for oral use. One tablet per intake, once daily (approximately at the same time). The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature.

    Drug: Anaferon for children

  • Placebo comparator
    Placebo

    Tablet for oral use. Placebo using Anaferon for children scheme.

    Drug: Placebo

Interventions

  • DrugAnaferon for children

    Tablet for oral use.

  • DrugPlacebo

    Tablet for oral use.

06

What researchers measure

Primary outcomes

  1. Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.

    Based on medical records.

    Time frame: in 12 weeks of the treatment

Secondary outcomes

  1. Percentage of Children Not Falling Ill With Influenza or Another ARVI.

    Based on medical records. Influenza/ARVI criteria are the following: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/weakness, headache, and chills), and at least one respiratory symptom (runny nose, nasal stuffiness, hoarseness/husky voice, sore throat, and cough).

    Time frame: in 12 weeks of the treatment

  2. Percentage of Children With the Symptoms Requiring Antibacterial Therapy.

    Based on medical records. Percentage of children with the symptoms of a respiratory or ear-nose-throat bacterial infection requiring antibacterial therapy.

    Time frame: in 12 weeks of the treatment

  3. Percentage of Children Requiring Hospitalized for Influenza/ARVI.

    Based on medical records. Percentage of children hospitalized for influenza/ARVI or their complications.

    Time frame: in 12 weeks of the treatment

  4. Presence and Type of Adverse Events (AE).

    Based on medical records. Presence and type of adverse events, their severity, relation to investigational drug, outcomes.

    Time frame: in 12 weeks of the treatment

07

Results

Posted May 6, 2020

Participant flow

Participant flow — Overall Study
MilestoneAnaferon for ChildrenPlacebo
Started528508
Completed520501
Not completed87
Withdrew: Сompliance with exclusion criteria87

Outcome measures

PrimaryTime From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.

Based on medical records.

Time frame:
in 12 weeks of the treatment
Reported as:
Mean · days
Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.
daysAnaferon for ChildrenPlacebo
Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.428.8 (351.0 to 523.8)275.8 (232.7 to 326.9)
Statistical analysis
  • Anaferon for Children vs Placebo · Regression, Logistic · p = 0.001Comparison performed on the regression parameters scale. Estimates for mean time obtained under assumption of exponentially distributed time-to-event.
  • Anaferon for Children vs Placebo · Regression, Cox · p = 0.0218 · Hazard ratio (hr): 0.645 · 95% CI 0.496 to 0.839Lower HR is better
SecondaryPercentage of Children Not Falling Ill With Influenza or Another ARVI.

Based on medical records. Influenza/ARVI criteria are the following: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/weakness, headache, and chills), and at least one respiratory symptom (runny nose, nasal stuffiness, hoarseness/husky voice, sore throat, and cough).

Time frame:
in 12 weeks of the treatment
Reported as:
Count of participants · Participants
Percentage of Children Not Falling Ill With Influenza or Another ARVI.
ParticipantsAnaferon for ChildrenPlacebo
4 weeks516452
8 weeks482415
12 weeks424368
Statistical analysis
  • Anaferon for Children vs Placebo · Fisher Exact · p = 0.0003 (Adjusted with Holm method for multiple comparrisons)
  • Anaferon for Children vs Placebo · Fisher Exact · p = 0.0003
  • Anaferon for Children vs Placebo · Fisher Exact · p = 0.0021
SecondaryPercentage of Children With the Symptoms Requiring Antibacterial Therapy.

Based on medical records. Percentage of children with the symptoms of a respiratory or ear-nose-throat bacterial infection requiring antibacterial therapy.

Time frame:
in 12 weeks of the treatment
Reported as:
Count of participants · Participants
Percentage of Children With the Symptoms Requiring Antibacterial Therapy.
ParticipantsAnaferon for ChildrenPlacebo
Percentage of Children With the Symptoms Requiring Antibacterial Therapy.38
Statistical analysis
  • Anaferon for Children vs Placebo · Fisher Exact · p = 0.1372
SecondaryPercentage of Children Requiring Hospitalized for Influenza/ARVI.

Based on medical records. Percentage of children hospitalized for influenza/ARVI or their complications.

Time frame:
in 12 weeks of the treatment
Reported as:
Count of participants · Participants
Percentage of Children Requiring Hospitalized for Influenza/ARVI.
ParticipantsAnaferon for ChildrenPlacebo
Percentage of Children Requiring Hospitalized for Influenza/ARVI.00
Statistical analysis
  • Anaferon for Children vs Placebo · Fisher Exact · p = >0.999
SecondaryPresence and Type of Adverse Events (AE).

Based on medical records. Presence and type of adverse events, their severity, relation to investigational drug, outcomes.

Time frame:
in 12 weeks of the treatment
Reported as:
Count of participants · Participants
Presence and Type of Adverse Events (AE).
ParticipantsAnaferon for ChildrenPlacebo
Mild severity6554
Moderate severity44
Statistical analysis
  • Anaferon for Children vs Placebo · Fisher Exact · p = >0.999

Adverse events

Collected over Adverse/Serious adverse events were registered during 12 weeks therapy.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anaferon for Children0/528 (0%)1/528 (0.2%)49/528 (9.3%)
Placebo0/508 (0%)0/508 (0%)44/508 (8.7%)
Most frequent serious events
Most frequent serious events
EventAnaferon for ChildrenPlacebo
Partial crampsNervous system disorders1/5280/508
Most frequent other events
Showing 10 of 47
Most frequent other events
EventAnaferon for ChildrenPlacebo
Chicken poxInfections and infestations4/5288/508
FeverGeneral disorders7/5280/508
Acute nasopharyngitisInfections and infestations6/5283/508
Runny noseRespiratory, thoracic and mediastinal disorders6/5282/508
Productive coughRespiratory, thoracic and mediastinal disorders5/5282/508
Respiratory viral infectionInfections and infestations3/5284/508
Acute respiratory tract infectionInfections and infestations4/5284/508
Allergic rashSkin and subcutaneous tissue disorders0/5283/508
TeethingGastrointestinal disorders3/5281/508
Functional gastrointestinal pathologyGastrointestinal disorders3/5281/508

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Anaferon for ChildrenPlaceboTotal
<=18 years5205011021
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Anaferon for ChildrenPlaceboTotal
Mean3.1 ± 1.73.1 ± 1.73.1 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)Anaferon for ChildrenPlaceboTotal
Female263244507
Male257257514
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Anaferon for ChildrenPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Anaferon for ChildrenPlaceboTotal
Uzbekistan151530
Russia505486991
08

Study locations

33 sites
  • Municipal Autonomous Institution "Children's City Clinical Hospital No. 11"
    Ekaterinburg, 620028, Russian Federation
  • Regional budgetary health care institution "Regional Children's Clinical Hospital"
    Ivanovo, 153040, Russian Federation
  • Republican Children's Clinical Hospital of the Ministry of Health of the Udmurt Republic
    Izhevsk, 426009, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation
    Kazan, 420012, Russian Federation
  • Kazan Federal University
    Kazan, 420012, Russian Federation
  • Federal Budget Institution of Science "Central Research Institute of Epidemiology" of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance
    Moscow, 111123, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation
    Moscow, 117997, Russian Federation
  • State Federal-Funded Educational Institution of Higher Professional Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
    Moscow, 119991, Russian Federation
  • LLC Center for Vaccine Prevention "DIAVAKS"
    Moscow, 129515, Russian Federation
  • Limited Liability Company "Gubernskiy lekar'"
    Murmansk, 183038, Russian Federation
  • Limited Liability Company "MDP-Medical Group"
    Odintsovo, 143005, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Orenburg State Medical University" of the Ministry of Healthcare of the Russian Federation
    Orenburg, 460000, Russian Federation
  • Municipal Health Care Institution "City Child Health Clinical Polyclinic №5"
    Perm, 614066, Russian Federation
  • Municipal Budgetary Health Care Institutions "Semashko City Hospital №1 Rostov-on-Don "
    Rostov-na-Donu, 344000, Russian Federation
  • Municipal budgetary health care institution "Children's city polyclinic №4"
    Rostov-na-Donu, 344065, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "Children's City Polyclinic No. 44"
    Saint Petersburg, 191144, Russian Federation
  • St. Petersburg State Budgetary Health Care Institution "Сity Polyclinic №44"
    Saint Petersburg, 192212, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical Academy" of Ministry of Health of Russian Federation
    Saint Petersburg, 194100, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "Children's City Polyclinic No. 35"
    Saint Petersburg, 196191, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "Children's City Hospital No. 22"
    Saint Petersburg, 196650, Russian Federation
  • Samara Regional Children's Sanatorium "Yunost'"
    Samara, 443031, Russian Federation
  • State Budgetary Institution of Health of the Samara Region "Samara City Children's Clinical Hospital No. 1 named after N.N. Ivanova"
    Samara, 443079, Russian Federation
  • Limited Liability Company "DNA Research Center"
    Saratov, 410005, Russian Federation
  • Regional State Autonomous Healthcare Institution "Children's Hospital №1"
    Tomsk, 634050, Russian Federation
  • Siberian State Medical University
    Tomsk, 634050, Russian Federation
  • Bashkir State Medical University
    Ufa, 450008, Russian Federation
  • Volgograd State Medical University/Departmental Clinical Hospital at Volgograd-1 Station of Russian Railways
    Volgograd, 400131, Russian Federation
  • Volgograd State Medical University/Volgograd Regional Clinical Hospital # 1
    Volgograd, 400131, Russian Federation
  • Yaroslavl State Medical University/Children's Clinic # 5
    Yaroslavl, 150000, Russian Federation
  • Yaroslavl State Medical University/Clinical Hospital # 8 (Children's Clinic # 1)
    Yaroslavl, 150000, Russian Federation
  • Yaroslavl State Medical University/Department of Infectious Diseases, Epidemiology and Children's Diseases
    Yaroslavl, 150000, Russian Federation
  • Yaroslavl State Medical University/Regional Children's Clinical Hospital # 8 (Children's Clinic # 2)
    Yaroslavl, 150000, Russian Federation
  • Family polyclinic № 6
    Tashkent, 100194, Uzbekistan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in May 2019, 19 months.

Results were first posted in May 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 4, 2017
StartActual
Oct 3, 2017
Primary completionActual
May 20, 2019
CompletionActual
May 20, 2019
Results first posted
May 6, 2020
Last update
May 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03301155
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Oct 3, 2017
Primary completion
May 20, 2019
Completion
May 20, 2019
Results posted
May 6, 2020
Last update
May 6, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion